Tumor Lysis Syndrome in Solid and Hematologic Malignancies: A Guide for Early Detection and Intervention

Area of Science:

• Oncology
• Nephrology
• Critical Care Medicine

Background:

• Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency.
• It is characterized by severe metabolic derangements including hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia.
• TLS is commonly associated with hematologic malignancies.

Purpose of the Study:

• To review the pathophysiology, clinical manifestations, and management strategies for TLS.
• To highlight the importance of early diagnosis and intervention in preventing severe complications.
• To discuss current treatment guidelines and emerging therapeutic approaches.

Main Methods:

• Literature review of existing studies and clinical guidelines on TLS.
• Analysis of case reports and clinical trial data related to TLS management.
• Synthesis of information on diagnostic criteria and therapeutic interventions.

Main Results:

• TLS is characterized by rapid release of intracellular contents following tumor cell śmierci.
• Metabolic abnormalities can lead to acute kidney injury, cardiac arrhythmias, and seizures.
• Prophylaxis with hydration and uric acid-lowering agents is crucial for high-risk patients.

Conclusions:

• Effective management of TLS requires a multidisciplinary approach involving oncologists, nephrologists, and critical care physicians.
• Early identification of risk factors and prompt initiation of preventive measures can significantly reduce TLS incidence and severity.
• Continued research is needed to optimize TLS treatment and improve patient outcomes.